Antibioprophylaxis for Excision-graft Surgery in Burn Patient (A2B-TRIAL)

Recruiting Phase 3 Interventional Study
Burns Surgery
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 99
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
506 (estimated)
Sponsor
Assistance Publique - Hôpitaux de Paris · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The indication of antibiotic prophylaxis in burn patients remains highly controversial and hasn't reached a consensus. The objective of antibiotic prophylaxis would be to reduce the risk of post-operative local and systemic infections. Burn surgery is associated with a high risk of bacteremia and postoperative infections and sepsis. However, antibiotic prophylaxis exposes to the risk of selecting …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patient over 18 years and less than 80 years old * Burned patients requiring at least one excision-graft surgery * Burn TBSA% between 5% and 40% * Signed informed consent or inclusion under the emergency provisions of the law (article L1122-1-2 of the CSP) Exclusion Criteria:…
Contacts

François DEPRET, MD

01 42 49 95 70

francois.depret@aphp.fr

CONTACT

Matthieu LEGRAND, MD-PhD

01 42 49 95 70

matthieu.m.legrand@gmail.com

CONTACT